Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial

Roche, Nicolas; Chapman, Kenneth R.; Vogelmeier, Claus F.; Herth, Felix J. F.; Chau Thach; Fogel, Robert; Olsson, Petter; Patalano, Francesco; Banerji, Donald; Wedzicha, Jadwiga A.; Thach, Chau
May 2017
American Journal of Respiratory & Critical Care Medicine;5/1/2017, Vol. 195 Issue 9, p1189
Academic Journal
journal article
Rationale: Post hoc analyses suggest that blood eosinophils have potential as a predictive biomarker of inhaled corticosteroid efficacy in the management of chronic obstructive pulmonary disease (COPD).Objectives: We prospectively investigated the value of blood eosinophils as a predictor of responsiveness to an inhaled corticosteroid/long-acting β2-agonist combination versus a long-acting β2-agonist/long-acting muscarinic antagonist combination for exacerbation prevention.Methods: We conducted prespecified analyses of data from the FLAME (Effect of Indacaterol Glycopyronium vs Fluticasone Salmeterol on COPD Exacerbations) study, which compared once-daily long-acting β2-agonist/long-acting muscarinic antagonist indacaterol/glycopyrronium 110/50 μg with twice-daily long-acting β2-agonist/inhaled corticosteroid salmeterol/fluticasone combination 50/500 μg in patients with one or more exacerbations in the preceding year. Subsequent post hoc analyses were conducted to address further cutoffs and endpoints.Measurements and Main Results: We compared treatment efficacy according to blood eosinophil percentage (<2% and ≥2%, <3% and ≥3%, and <5% and ≥5%) and absolute blood eosinophil count (<150 cells/μl, 150 to <300 cells/μl, and ≥300 cells/μl). Indacaterol/glycopyrronium was significantly superior to salmeterol/fluticasone for the prevention of exacerbations (all severities, or moderate or severe) in the <2%, ≥2%, <3%, <5%, and <150 cells/μl subgroups, and at no cutoff was salmeterol/fluticasone superior to indacaterol/glycopyrronium. Furthermore, the rate of moderate or severe exacerbations did not increase with increasing blood eosinophils. The incidence of pneumonia was higher in patients receiving salmeterol/fluticasone than indacaterol/glycopyrronium in both the <2% and ≥2% subgroups.Conclusions: Our prospective analyses indicate that indacaterol/glycopyrronium provides superior or similar benefits over salmeterol/fluticasone regardless of blood eosinophil levels in patients with COPD. Clinical trial registered with www.clinicaltrials.gov (NCT01782326).


Related Articles

  • Lumacaftor/Ivacaftor in Patients Aged 6-11 Years with Cystic Fibrosis and Homozygous for F508del-CFTR. Milla, Carlos E.; Ratjen, Felix; Marigowda, Gautham; Fang Liu; Waltz, David; Rosenfeld, Margaret; Liu, Fang; VX13-809-011 Part B Investigator Group * // American Journal of Respiratory & Critical Care Medicine;4/1/2017, Vol. 195 Issue 7, p912 

    Rationale: Combination lumacaftor/ivacaftor has been shown to improve lung function and other endpoints in patients aged 12 years and older with cystic fibrosis and homozygous for F508del-CFTR, but it has not been assessed in younger patients.Objectives: In this...

  • Pedometer Step Count Targets during Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease. A Randomized Controlled Trial. Nolan, Claire M.; Maddocks, Matthew; Canavan, Jane L.; Jones, Sarah E.; Delogu, Veronica; Kaliaraju, Djeya; Banya, Winston; Kon, Samantha S. C.; Polkey, Michael I.; Man, William D.-C. // American Journal of Respiratory & Critical Care Medicine;5/15/2017, Vol. 195 Issue 10, p1344 

    Rationale: Increasing physical activity is a key therapeutic aim in chronic obstructive pulmonary disease (COPD). Pulmonary rehabilitation (PR) improves exercise capacity, but there is conflicting evidence regarding its ability to improve physical activity levels.Objectives:...

  • Comparison of Helicobacter pylori Eradication Rates of 2-Week Levofloxacin-Containing Triple Therapy, Levofloxacin-Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First-Line Regimen. Kahramanoğlu Aksoy, Evrim; Pirinçci Sapmaz, Ferdane; Göktaş, Zeynep; Uzman, Metin; Nazlıgül, Yaşar; Kahramanoğlu Aksoy, Evrim; Pirinçci Sapmaz, Ferdane; Göktaş, Zeynep; Nazlıgül, Yaşar // Medical Principles & Practice;Feb2018, Vol. 26 Issue 6, p523 

    Objective: The aim of this study was to compare the efficacy and safety of 2-week levofloxacin-containing triple therapy, levofloxacin-containing bismuth quadruple therapy, and standard bismuth-containing quadruple therapy as a first-line regimen for the eradication of Helicobacter...

  • Changes to inhaled corticosteroid dose when initiating combination inhaler therapy in long-acting β agonist-naïve patients with asthma: a retrospective database analysis. Covvey, Jordan R.; Johnston, Blair F.; Wood, Fraser; Boyter, Anne C. // Thorax;Nov2014, Vol. 69 Issue 11, p1056 

    Retrospective prescribing data were obtained from 46 general practice surgeries in NHS Scotland. Patients with asthma who were naïve to previous long-acting ß agonist therapy and initiated combination inhaler therapy in 2008-2009 were classified according to the inhaled corticosteroid...

  • Steroid-sparing effect of pimecrolimus cream 1% in children with severe atopic dermatitis. Zuberbier, Torsten; Heinzerling, Lucie; Bieber, Thomas; Schauer, Uwe; Klebs, Sven; Bräutigam, Matthias; Bräutigam, Matthias // Dermatology (10188665);Dec2007, Vol. 215 Issue 4, p325 

    Objective: To investigate if pimecrolimus cream 1% reduces the need for steroids in the long-term management of severe pediatric atopic dermatitis (AD).Methods: A total of 184 pediatric patients (aged 2-17 years) with a history of severe AD according to Rajka and...

  • Effect of Fluticasone Furoate and Vilanterol on Exacerbations of Chronic Obstructive Pulmonary Disease in Patients with Moderate Airflow Obstruction. Martinez, Fernando J.; Vestbo, Jørgen; Anderson, Julie A.; Brook, Robert D.; Celli, Bartolome R.; Cowans, Nicholas J.; Crim, Courtney; Dransfield, Mark; Kilbride, Sally; Yates, Julie; Newby, David E.; Niewoehner, Dennis; Calverley, Peter M. A.; SUMMIT Investigators // American Journal of Respiratory & Critical Care Medicine;4/1/2017, Vol. 195 Issue 7, p881 

    Rationale: Inhaled corticosteroids have been shown to decrease exacerbations in patients with moderate to severe chronic obstructive pulmonary disease (COPD). Their effects in patients with milder airflow obstruction remain unclear.Objectives: This was an analysis of...

  • How Do Dual Long-Acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease? Beeh, Kai M.; Burge, Pierre-Regis; Franssen, Frits M. E.; Lopez-Campos, Jose Luis; Loukides, Stelios; Hurst, John R.; Fležar, Matjaž; Ulrik, Charlotte Suppli; Di Marco, Fabiano; Stolz, Daiana; Valipour, Arschang; Casserly, Brian; Ställberg, Björn; Kostikas, Konstantinos; Wedzicha, Jadwiga A.; Burgel, Pierre-Regis // American Journal of Respiratory & Critical Care Medicine;7/15/2017, Vol. 196 Issue 2, p139 

    Decreasing the frequency and severity of exacerbations is one of the main goals of treatment for patients with chronic obstructive pulmonary disease. Several studies have documented that long-acting bronchodilators can reduce exacerbation rate and/or severity, and others have shown that...

  • A Multicenter Randomized Trial Assessing the Efficacy of Helium/Oxygen in Severe Exacerbations of Chronic Obstructive Pulmonary Disease. Jolliet, Philippe; Ouanes-Besbes, Lamia; Abroug, Fekri; Khelil, Jalila Ben; Besbes, Mohamed; Garnero, Aude; Arnal, Jean-Michel; Daviaud, Fabrice; Chiche, Jean-Daniel; Lortat-Jacob, Benoît; Diehl, Jean-Luc; Lerolle, Nicolas; Mercat, Alain; Razazi, Keyvan; Brun-Buisson, Christian; Durand-Zaleski, Isabelle; Texereau, Joëlle; Brochard, Laurent; Ben Khelil, Jalila; E.C.H.O.ICU Trial Investigators // American Journal of Respiratory & Critical Care Medicine;4/1/2017, Vol. 195 Issue 7, p871 

    Rationale: During noninvasive ventilation (NIV) for chronic obstructive pulmonary disease (COPD) exacerbations, helium/oxygen (heliox) reduces the work of breathing and hypercapnia more than air/O2, but its impact on clinical outcomes remains unknown.Objectives: To...

  • Acute blocking of naloxone-precipitated opiate withdrawal symptoms by methohexitone. Loimer, N.; Schmid, R.; Lenz, K.; Presslich, O.; Grünberger, J.; Grünberger, J // British Journal of Psychiatry;Nov90, Vol. 157, p748 

    In a double-blind placebo-controlled trial of 18 patients, methohexitone blocked objective signs of opiate withdrawal caused by a bolus injection of naloxone. Furthermore, in continuing the naloxone therapy for 48 hours, no withdrawal signs appeared. Levels of withdrawal distress returned to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics